“This is probably once in a generation technology that we see every 30 or 40 years that could completely transform the health system, and in fact has the potential to transform humanity.”
Dr. Samarth Kulkarni has served as the Chief Executive Officer of CRISPR Therapeutics since 2017. He has significant expertise in strategy and operations in biotech and a wide range of related cutting-edge therapeutic technologies.
Kulkarni joined CRISPR in 2015 in the early stages of the company as Chief Business Officer, and then was appointed to President and Chief Business Officer before becoming CEO. Prior to joining, Kulkarni was a Partner at McKinsey & Company, where he had a leading role in the Pharmaceutical and Medical products practice. While at McKinsey, he co-led the biotech practice, where he focused on strategy and operations, and led initiatives in areas such as personalized medicine and immunotherapy. Previously, Kulkarni served as the Chairman of the Board of Directors of Casebia Therapeutics, a joint subsidiary formed by CRISPR Therapeutics and Bayer. He currently serves on the Board of Directors of two precision oncology companies, Black Diamond Therapeutics and Repare Therapeutics. He also serves on the Board of the Emerging Companies Section of the Biotechnology Innovation Organization (BIO).
Kulkarni received a Ph.D. in Bioengineering and Nanotechnology from the University of Washington and a B. Tech. from the Indian Institute of Technology.